# Pliant Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2020

- Company: [Pliant Therapeutics, Inc.](/companies/plrx.md) (CIK 1746473)
- Form: 10-Q
- Filed: 2020-08-11
- Accepted by EDGAR: Aug 11, 2020, 16:24 ET
- Period: 2020-06-30
- Accession: 0001564590-20-039327
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1746473/000156459020039327/plrx-10q_20200630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1746473/000156459020039327/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-01 to 2020-06-30 | $3.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2020-01-01 to 2020-06-30 | $32.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2020-04-01 to 2020-06-30 | $17.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2020-01-01 to 2020-06-30 | $31.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-04-01 to 2020-06-30 | −$17.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-01-01 to 2020-06-30 | −$6.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-04-01 to 2020-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-01-01 to 2020-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-04-01 to 2020-06-30 | −$17.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-01-01 to 2020-06-30 | −$6.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-04-01 to 2020-06-30 | −$1.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2020-01-01 to 2020-06-30 | −$0.85 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-04-01 to 2020-06-30 | −$1.39 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2020-01-01 to 2020-06-30 | −$0.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-04-01 to 2020-06-30 | 12,253,943 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2020-01-01 to 2020-06-30 | 7,062,780 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2020-01-01 to 2020-06-30 | −$5.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-01 to 2020-06-30 | $622.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-06-30 | $178.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-30 | $324.3m | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-30 | $328.8m | us-gaap:Assets |
| Current liabilities | at 2020-06-30 | $12.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-06-30 | $13.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-06-30 | $315.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1746473/000156459020039327/plrx-10q_20200630.htm

Filed Aug 11, 2020.
Source: SEC EDGAR, the filing index for accession 0001564590-20-039327. Last ingested by Listed: Nov 13, 2026, 15:38 ET. No prices; not investment advice.
